insulin biosimilar launched in Australia by biocon, mylan

Bio-technology major Biocon and pharmaceutical firm Mylan N V proclaimed the launch of insulin glargine biosimilar Semglee, indicated for the treatment of diabetes, in Australia.

Semglee is that the 1st insulin glargine biosimilar accessible on the Pharmaceutical advantages theme (PBS) in Australia, the businesses aforementioned in a joint statement.

We are extraordinarily excited to change reasonable access to Semglee, a p....